Looking ahead, this work sets the stage for expanded investigations into the mechanisms of flavonol-mediated DYRK1A inhibition and their therapeutic potential in preclinical models of DYRK1A-associated diseases, such as Alzheimer’s disease, Down syndrome and cancer. Here, DYRK1A is linked to early-onset autosomal dominant Alzheimer disease.